Hoechst AG | Jotup

Bioforum Expands Leadership Team with Appointment of Michael Goedde as President

Retrieved on:

Tuesday, March 19, 2024

NESS ZIONA, Israel, March 19, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the appointment of Michael Goedde as its President. A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.

Key Points:

A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.
"As we expand our presence in North America and around the world, I'm delighted to welcome Michael to the Bioforum family and confident that his leadership will be invaluable in driving our long-term growth and success."
Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations.
He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in Frankfurt, Germany.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on:

Tuesday, February 27, 2024

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points:

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
“Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Final Days to Register for the 2 Day Online Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World Training Course (March 7-8, 2024)

Retrieved on:

Monday, February 12, 2024

Master of Science, School, Bachelor of Science, RQA, Euromed, Doctor of Philosophy, Hoechst AG, Clinical research, Medication, University, Pharmacy school, Phoenix International Holdings, Integrity, Fine chemical

What are the core competencies of effective leaders in the pharmaceutical industry?

Key Points:

What are the core competencies of effective leaders in the pharmaceutical industry?
She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.
She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.
She regularly writes on pharmaceutical regulatory issues including "The Planning of International Drug Development", in the Clinical Research Manual, Euromed and the "Impact of Brexit", RQA Journal 2017.

Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World Training Course (Online Event) - ResearchAndMarkets.com

Retrieved on:

Tuesday, February 6, 2024

Biotechnology, Health, Pharmaceutical, Training, Education, Bachelor of Science, Euromed, School, Pharmacy school, Hoechst AG, Medication, Phoenix International Holdings, Master of Science, RQA, Doctor of Philosophy, University, Integrity, Clinical research, Fine chemical

What are the core competencies of effective leaders in the pharmaceutical industry?

Key Points:

What are the core competencies of effective leaders in the pharmaceutical industry?
She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.
She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.
She regularly writes on pharmaceutical regulatory issues including "The Planning of International Drug Development", in the Clinical Research Manual, Euromed and the "Impact of Brexit", RQA Journal 2017.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Retrieved on:

Friday, December 22, 2023

HEC Paris, Hoechst AG, AstraZeneca, Business, Research, Merck & Co., Vaccine, MBA, Chemical engineering, Therapy, Euronext, GSK, University, Moses Austin, Merck, Patient, Alexion, Pharmaceutical industry

At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.

Key Points:

At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.
The Company’s shareholders also approved the appointments of Mr. Marc Dunoyer and Dr. Tyrell Rivers as directors of the Cellectis board of directors, which appointment remains subject to the completion of the Additional Investment.
“We are grateful to our shareholders for supporting the Additional Investment and we are looking forward to welcoming Mr. Dunoyer and Dr. Rivers to our board of directors.
The detailed results of the vote and the resolutions are available on Cellectis’ website:

Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

Retrieved on:

Tuesday, November 14, 2023

Hoechst AG, NYSE, Quality, Merck & Co., Ashland Global, Sanofi, Biophysical environment, MRK, Merck, Health, Safety

WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE: MRK) to its Board of Directors.

Key Points:

WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE: MRK) to its Board of Directors.
Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.
Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.
“I am pleased to welcome Sanat as a new director to the Ashland Board,” said Guillermo Novo, chair and chief executive officer, Ashland.

2023 CAPA (Corrective and Preventative Action) Procedures Training Course: How to Improve your Processes and Implement and Document an Effective CAPA Quality System

Retrieved on:

Friday, October 27, 2023

Euromed, Predicted impact of Brexit, Clinical research, Integrity, Bachelor of Science, Pharmacy school, Doctor of Philosophy, Phoenix International Holdings, School, Hoechst AG, RQA, University, Master of Science, Medication, Pharmaceutical industry, Pharmacy

Implementation - execute the action plan, eg stakeholder analysis, the transition curve

Key Points:

Implementation - execute the action plan, eg stakeholder analysis, the transition curve
Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff.
She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.
She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.
She regularly writes on pharmaceutical regulatory issues including 'The Planning of International Drug Development', in the Clinical Research Manual, Euromed and the 'Impact of Brexit', RQA Journal 2017.

2023 CAPA (Corrective and Preventative Action) Procedures Training Course: How to Improve your Processes and Implement and Document an Effective CAPA Quality System - ResearchAndMarkets.com

Retrieved on:

Friday, July 7, 2023

Implementation - execute the action plan, eg stakeholder analysis, the transition curve

Key Points:

Implementation - execute the action plan, eg stakeholder analysis, the transition curve
Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff.
She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.
She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.
She regularly writes on pharmaceutical regulatory issues including "The Planning of International Drug Development", in the Clinical Research Manual, Euromed and the "Impact of Brexit", RQA Journal 2017.

The Pharma Mini MBA Training Course: Featuring Business School Pharmaceutical Case Studies

Retrieved on:

Friday, April 21, 2023

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.

Key Points:

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.
This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement.
Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff.

The Pharma Mini MBA Training Course: Accelerated Management Programme for Pharmaceutical Industry Employees - ResearchAndMarkets.com

Retrieved on:

Wednesday, April 19, 2023

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.

Key Points:

BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis.
This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team.
She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement.
She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry.